Product image of Icatibant Stada Arzneimittel Ag (Icatibant) supplied by GNH India

Icatibant Stada Arzneimittel Ag

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Stada Arzneimittel Ag (Icatibant)

Icatibant, the active ingredient in Icatibant Stada Arzneimittel Ag, is a bradykinin B2 receptor antagonist presented as an injection for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with a confirmed diagnosis.

GNH India supplies Icatibant Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant acts on the bradykinin pathway to control swelling associated with hereditary angioedema.

  • Hereditary angioedema type I: provides rapid relief of acute swelling episodes.
  • Hereditary angioedema type II: reduces the duration and severity of attacks.
  • Hereditary angioedema with normal C1‑inhibitor: alleviates symptoms during acute episodes.

How It Works

  • Icatibant is a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks bradykinin‑mediated vasodilation and increased vascular permeability, thereby preventing the plasma leakage and tissue swelling that characterize hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Erythema: localized redness around the injection area.
  • Swelling: transient edema at the site of administration.
  • Nausea: occasional feeling of queasiness.
  • Headache: mild to moderate head pain.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, urticaria, or angioedema.
  • Anaphylaxis: severe, potentially life‑threatening allergic response.
  • Severe hypotension: marked drop in blood pressure.
  • Thrombocytopenia: low platelet count.
  • Infection at injection site: cellulitis or abscess formation.
  • Cardiovascular events: rare chest pain or arrhythmia.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Pregnancy: safety not established; avoid unless benefit outweighs risk.
  • Breastfeeding: unknown excretion; weigh potential risks to infant.
  • Renal impairment: use with caution; monitor renal function.
  • Concomitant ACE inhibitors: increased bradykinin may heighten adverse effects; monitor closely.
  • Known hypersensitivity: discontinue if severe allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medicines that influence bradykinin pathways or cardiovascular function.

Major Interactions (Avoid)

  • ACE inhibitors: may raise bradykinin levels, increasing risk of angioedema.
  • Angiotensin receptor blockers: similar risk of enhanced bradykinin activity.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may mask pain, requiring careful assessment.
  • Estrogen‑containing contraceptives: can affect hereditary angioedema severity.
  • Other bradykinin antagonists: additive pharmacologic effect may require dose adjustment.

Frequently Asked Questions

Icatibant is used to treat acute attacks of hereditary angioedema, a rare genetic disorder that causes sudden swelling of the skin and mucosal tissues. It works by rapidly reducing the swelling associated with these episodes.

Icatibant blocks the bradykinin B2 receptor, preventing bradykinin from causing blood vessels to dilate and become more permeable. This inhibition stops the fluid leakage that leads to swelling during hereditary angioedema attacks.

The dose of Icatibant is determined by the prescribing clinician based on the patient’s condition and clinical guidelines. The medication is administered as a subcutaneous injection, and the prescriber sets the exact amount and frequency.

Safety data for Icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates replace the deficient protein. Icatibant offers rapid subcutaneous administration and works directly on the bradykinin pathway, providing an alternative for patients who prefer or require a non‑plasma‑derived therapy.

Icatibant should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the product. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes before use.

Icatibant is given as a single subcutaneous injection into the abdomen, thigh or upper arm. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of thrombocytopenia. Patients should be monitored for signs of allergic reaction or sudden blood pressure changes after administration.

Icatibant is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Patients with uncontrolled cardiovascular disease or those taking ACE inhibitors without medical supervision should avoid use until evaluated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT